RWE, Market Access, Pricing & Reimbursement Global Congress 2022 Europe
Agenda at a Glance
Day 2 - Congress
Day 2: Wednesday 2nd March 2022
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
CHALLENGES & OPPORTUNITIES
- Advantages of market access teams in payer relationship
- Payer evidence requirement in early development
- Best practices to obtain better pricing and reimbursement
- Strategies to improve a better payer relationship
Moderator:
Panellist:
- Andrew Stainthorpe, Head of Market Access, Oxford AHSN
- Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
- Unlocking data from early access
- Effective communications with internal and external stakeholders
- Embracing the digital vision
- Future trends and developments in the healthcare distribution
Sjaak Vink, Chief Executive Officer, The SocialMedwork
- New cell and gene therapies are often characterized by fat tail probability functions (i.e. small probability
of very large gains) - Traditional statistical methods are often not appropriate in this context to determine value.
- Instead, patient preferences are key. They should be systematically included in regulatory and
reimbursement decisions.
Jörg Mahlich, Market Access & Government Affairs Lead, Miltenyi Biomedicine
- Innovative approaches required to address the medicine access challenge
- Lessons to be learned from best practices in the field of pricing and reimbursement of medicines
- The value of list prices against the backdrop of external price referencing and managed entry
agreements. - Innovative policy options that need to be developed, agreed upon and implemented.
Moderator:
Andrew Stainthorpe, Head of Market Access, Oxford AHSN
Panellist:
Olga Katzelnik, Market Access Lead Europe/International, Regeneron
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
Jörg Mahlich, Market Access & Government Affairs Lead, Miltenyi Biomedicine
- Why, when and how could you collaborate for access
- Overcoming barriers to collaboration
- What can we learn from Duchenne UK’s project HERCULES?
Josie Godfrey, Co-Founder and CEO, Realise Advocacy
- Why is this important
- Current state of play
- Barriers to Equity Pricing
- Potential solutions and some principles to maximize impact of Equity Pricing
Ana Plata, Global Pricing Head, AstraZeneca Biopharmaceuticals
- Objective: Activating the full stakeholder ecosystem to shift conversation from price to value to get access to
innovative therapies - Why is the full stakeholder ecosystem important for gaining access in the future?
- How to Identify the stakeholder ecosystem for access success
- Step by step: Setting up a cross-functional program for access success
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
- The importance of making MA the core of the company
- Bridge between pre-launch strategy and post-launch
- International Drug Price Indicator Guide WHO
- Increasing collaboration between EU countries
- Frontiers in Health Care
- What will the future bring?
Panellist:
Andrew Stainthorpe, Head of Market Access, Oxford AHSN
Eugean Jiwanmall, Sr Research Analyst, Med. Policy & Tech Evaluation, Independence Blue Cross
Josie Godfrey, Co-Founder and CEO, Realise Advocacy